List of Advarra Clinical Conductor Customers
Columbia, 21044, MD,
United States
Since 2010, our global team of researchers has been studying Advarra Clinical Conductor customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Advarra Clinical Conductor for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Advarra Clinical Conductor for Clinical Trial Management include: Ascension, a United States based Healthcare organisation with 142000 employees and revenues of $28.55 billion, Velocity Clinical Research, a United States based Healthcare organisation with 1000 employees and revenues of $450.0 million, Eurofins Crl United States, a United States based Life Sciences organisation with 75 employees and revenues of $15.0 million and many others.
Contact us if you need a completed and verified list of companies using Advarra Clinical Conductor, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Advarra Clinical Conductor customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Ascension | Healthcare | 142000 | $28.6B | United States | Advarra | Advarra Clinical Conductor | Clinical Trial Management | 2022 | n/a |
In 2022 Ascension implemented Advarra Clinical Conductor in the United States, Apps Category . The deployment focused on clinical research finance and billing workflows within Ascension’s research operations.
The implementation leveraged Advarra Clinical Conductor’s billing and financial management capabilities to centralize billing reconciliation and sponsor invoicing processes. Configuration emphasized charge reconciliation, sponsor billing records, and financial tracking modules to surface previously unbilled activity and support auditability.
Operational coverage spanned clinical research finance and billing teams across Ascension’s sites in the United States, with the application embedded into routine billing and study closeout activities. The narrative does not specify technical integrations with other enterprise systems, the rollout model, or partner involvement.
Governance centered on embedding billing reconciliation workflows into the clinical trial management lifecycle, using Advarra Clinical Conductor to identify revenue leakage. As reported, Ascension used Advarra Clinical Conductor to identify and recover over $100,000 in previously unbilled sponsor revenue, demonstrating the system’s role in financial control for research billing.
|
 |
Eurofins Crl United States | Life Sciences | 75 | $15M | United States | Advarra | Advarra Clinical Conductor | Clinical Trial Management | 2019 | n/a |
In 2019, Eurofins Crl United States extended its use of Advarra Clinical Conductor within its Clinical Conductor CTMS environment to incorporate two-way participant messaging. Eurofins Crl United States had used Clinical Conductor CTMS for several years to track studies and subsequently adopted Advarra's CCText two-way communications module to re-engage lapsed panelists and improve outreach for U.S. operations.
The implementation embedded the CCText communications module directly with Advarra Clinical Conductor and Clinical Conductor CTMS, creating an integrated communications layer for study-level participant panels. Functional capabilities described in the vendor case study include two-way SMS messaging workflows, study tracking linked to participant records, and automated re-engagement sequencing for lapsed panelists, with CCText operating as an integrated messaging module in the CTMS application.
Integrations and operational coverage are focused on U.S. operations and participant-facing functions, with CCText usage documented as integrated with Clinical Conductor in the case study. The vendor case study reports a ~95% reach rate with CCText, and module adoption is presented as a use case for improving participant messaging and panelist re-engagement within the Clinical Conductor CTMS deployment.
|
 |
Velocity Clinical Research | Healthcare | 1000 | $450M | United States | Advarra | Advarra Clinical Conductor | Clinical Trial Management | 2022 | n/a |
In 2022, Velocity Clinical Research deployed Advarra Clinical Conductor as an enterprise Clinical Trial Management System across its U.S. site network. The rollout implemented Advarra Clinical Conductor Enterprise CTMS alongside eReg and eSource to centralize regulatory workflows, enrollment management, and patient data access.
The implementation configured Clinical Conductor to support study administration and regulatory document orchestration together with electronic registration and source data capture, aligning system capabilities with site-level operational processes. Configuration emphasis was on unified patient records and enrollment tracking, using eReg and eSource to feed a consolidated subject view within the Clinical Trial Management System.
Operational coverage spanned Velocity Clinical Research clinical operations, site coordinators, and regulatory teams across its national sites, with the public announcement in February 2022 describing the rollout and its intent. The program enabled Velocity to access unified patient data across its national sites and to scale site-level technology capabilities, improving visibility for regulatory, enrollment, and patient data access without reference to a named prior platform.
|
Buyer Intent: Companies Evaluating Advarra Clinical Conductor
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||